Comparing Efficacy and Safety of CTO0303 in Pediatric Subjects

Inclusion Criteria: * Pediatric or adolescent subjects those who get a written consent both whom and their parents (or legally acceptable representative) * Pediatric or adolescent subjects aged 4 to 15 years old based on date of written consent Exclusion Criteria: * Subjects with a history of severe systemic reaction or increased sensitivity to atropine * Subjects with anterior segment disease that interferes with ophthalmological examination (ex. corneal scar, corneal opacity and others) * Subjects administered mydriatic medication within 14 days prior to administration of Investigational Product * Subjects with contact lens